Two‐year outcome of ventricular assist device via a modified left atrium to aorta approach in cardiac amyloidosis
Abstract Cardiac amyloidosis is a debilitating disease associated with poor long‐term survival. Medical or palliative treatment is the usual course of therapy, but patients are often intolerant of conventional heart failure treatment. The current standard of care of sequential heart and bone marrow...
Main Authors: | Choon Pin Lim, Yeong Phang Lim, Chong Hee Lim, Hean‐Yee Ong, Daryl Tan, Abdul Razakjr Omar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-10-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.14039 |
Similar Items
-
Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management
by: Areez Shafqat, et al.
Published: (2024-03-01) -
Description of rare clinical case of AA-amyloidosis with involvement in pathological process of heart and lungs
by: Z. G. Tatarintseva, et al.
Published: (2020-03-01) -
Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure
by: Gabriela Molina O, et al.
Published: (2014-11-01) -
Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience
by: Dario Roccatello, et al.
Published: (2020-10-01) -
Histological Kidney Re-Evaluation after Daratumumab Monotherapy for AL Amyloidosis
by: Roberta Fenoglio, et al.
Published: (2022-06-01)